General Information of Drug (ID: DMJVL57)

Drug Name
XEN1101 Drug Info
Indication
Disease Entry ICD 11 Status REF
Epilepsy 8A60-8A68 Phase 1 [1]
Cross-matching ID
PubChem CID
24743936
TTD Drug ID
DMJVL57

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Retigabine DMGNYIH Behcet disease 4A62 Approved [2]
Linopirdine DM0ZOGX Cognitive impairment 6D71 Phase 3 [3]
ICA-105665 DMP925B Epilepsy 8A60-8A68 Phase 2 [4]
ICA-69673 DM1RZVI Pain MG30-MG3Z Preclinical [5]
[14C]TEA DM6SFYH Discovery agent N.A. Investigative [6]
PD-32577 DMBA15J Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated potassium channel Kv7.3 (KCNQ3) TTIVDM3 KCNQ3_HUMAN Activator [1]

References

1 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
2 The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels. Epilepsia. 2012 Apr;53(4):606-12.
3 The M-channel blocker linopirdine is an agonist of the capsaicin receptor TRPV1. J Pharmacol Sci. 2010;114(3):332-40.
4 New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Curr Neurol Neurosci Rep. 2008 Jul;8(4):345-52.
5 Voltage-gated Potassium Channels as Therapeutic Drug Targets
6 Differential tetraethylammonium sensitivity of KCNQ1-4 potassium channels. Br J Pharmacol. 2000 Feb;129(3):413-5.
7 Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.